T Hervig
Overview
Explore the profile of T Hervig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doughty H, Apelseth T, Sivertsen J, Annaniasen K, Hervig T
Transfus Med
. 2018 Apr;
28(5):357-362.
PMID: 29682837
Objectives: To describe the change in massive transfusion (MT) practice in a single Norwegian centre throughout the period 2002-2015. Background: MT support for traumatic haemorrhage has changed since the mid-2000s....
2.
Erikstein B, Hagen K, Hervig T
Transfus Med
. 2018 Jan;
29(3):169-178.
PMID: 29377396
Background And Objective: Although several studies focus on red blood cell (RBC) alloantibody distribution in selected patient populations, few address the specificity and frequency in all relevant groups. This study...
3.
Opheim E, Apelseth T, Stanworth S, Eide G, Hervig T
Vox Sang
. 2017 Jun;
112(6):578-585.
PMID: 28639693
Background And Objectives: Platelet count is used as a prophylactic platelet transfusion trigger, although evidence suggests that it is a poor predictor of bleeding. Thus, alternative tests are required. The...
4.
Wendelbo O, Netland Opheim E, Felli Lunde T, Bruserud O, Hervig T, Reikvam H
Vox Sang
. 2017 May;
112(5):484-486.
PMID: 28516477
The effects of fever on red cell transfusions are not well documented. In this pilot study, we have compared the outcome of red-blood-cell transfusions in haematologic patients with and without...
5.
van der Meer P, Couture C, Hervig T, Kruit G, Devine D, de Korte D, et al.
Vox Sang
. 2016 Dec;
112(1):9-17.
PMID: 28001293
Background: For a clinical platelet (PLT) transfusion trial conducted in three countries, the production of PLT concentrates (PCs) that were pathogen inactivated with the Mirasol technology was set up and...
6.
Frostad S, Bjerknes R, Hervig T, Nesthus I, Olweus J, Bruserud O
Hematology
. 2016 Jul;
4(3):217-29.
PMID: 27420550
The effect of insulin-like growth factor-1 (IGF-1) on highly enriched human apheresis CD34(+) progenitor cells was investigated in vitro. The progenitor cells were mobilized by treatment with cyclophosphamide + granulocyte-colony...
7.
Espinosa A, Arsenovic M, Hervig T, Sundic T, Aandahl A, Kronborg J, et al.
Transfus Apher Sci
. 2016 May;
54(3):422-7.
PMID: 27216542
Norway has recently established a working group to implement a national patient blood management (PBM) program. Although benchmarking regarding blood usage is challenging in Norway due to legal barriers, a...
8.
Knutson F, Osselaer J, Pierelli L, Lozano M, Cid J, Tardivel R, et al.
Vox Sang
. 2015 May;
109(4):343-52.
PMID: 25981525
Background And Objectives: A photochemical treatment process (PCT) utilizing amotosalen and UVA light (INTERCEPT(™) Blood System) has been developed for inactivation of viruses, bacteria, parasites and leucocytes that can contaminate...
9.
Bruserud O, Liseth K, Stamnesfet S, Cacic D, Melve G, Kristoffersen E, et al.
Transfus Med
. 2013 Aug;
23(6):397-406.
PMID: 23919332
Background: Hyperleukocytosis is usually defined as leukocyte count >100 × 10(9) L(-1) and can be seen in newly diagnosed leukaemias. Hyperleukocytic leukaemia is associated with a risk of organ failure...
10.
Reikvam H, van de Watering L, Prowse C, Devine D, Heddle N, Hervig T
Transfus Med
. 2010 Dec;
21(3):145-9.
PMID: 21143671
Objectives: Red blood cell concentrates (RCCs) are the major blood component transfused to patients. There is a great variability in patient response, depending on both the patient's blood volume and...